Disclosed are: a method for activating a helper T cell, which comprises the step of adding a WT1 peptide to an antigen-presenting cell to activate the helper T cell, wherein the WT1 peptide is capable of binding to any one selected from an HLA-DRB1*1501 molecule, an HLA-DPB1*0901 molecule and an HLA-DPB1*0501 molecule; a composition for use in the method; a therapeutic and/or prophylactic method for cancer by activating a helper T cell; a pharmaceutical composition for use in the therapeutic and/or prophylactic method; and others.

The present invention relates to a microtissue compartment device, comprising a compartment structure (1) having an upper surface (2) and a lower surface (3) essentially coplanar thereto, and at least two wells (4) suitable for accommodating one or more microtissues (5) in a liquid volume, each well having a lower section (4a) with a given diameter, coaxially oriented thereto an upper section (4b) with an extended diameter, and at least one conduit (6) fluidically connecting at least two wells to one another, and at least one space (13) arranged above a well. At least one well has, in its upper section, a relief structure (9) that prevents spreading or overflow of a liquid volume comprised in said well into space (13).

An electrode measuring the presence of an analyte is described as one embodiment. The electrode includes a working conductor with an electrode reactive surface and a first reactive chemistry that is responsive to the analyte. The electrode further includes a first transport material that enables flux of the first analyte to the first reactive chemistry and a second transport material that supplies a reactant to the first reactive chemistry. Wherein the first reactive chemistry does not contact the electrode reactive surface while at least partially shadowing a portion of the electrode reactive surface.

An electrode measuring the presence of an analyte is described as one embodiment. The electrode includes a working conductor with an electrode reactive surface and a first reactive chemistry that is responsive to the analyte. The electrode further includes a first transport material that enables flux of the first analyte to the first reactive chemistry and a second transport material that supplies a reactant to the first reactive chemistry. Wherein the first reactive chemistry does not contact the electrode reactive surface while at least partially shadowing a portion of the electrode reactive surface.

Systems and methods for predicting patient-specific responses to the administration of medicaments that are indicated to modulate megakaryocyte differentiation, proplatelet formation, and/or platelet production are disclosed. The systems and methods can include a three-dimensional bone marrow model that is composed of silk fibroin sponges including a protein of the extracellular matrix, such as fibrinogen. The methods include creating patient-specific megakaryocyte progenitors (or progenitors thereof), seeding those progenitors into the model, introducing the medicament to the progenitors within one model, perfusing the model with a cell culture medium, maturing the progenitors, comparing platelet generation from the model including the medicament to a control model, and generating a report having a prediction of in vivo efficacy based on the comparison.

Disclosed are methods for increasing the fertilization rate of an oocyte in a granulosa cell-oocyte complex, and/or the success rate of in-vitro fertilization by using mitochondrial therapies. Also disclosed are methods of identifying compounds for fertility treatment.

The present invention relates to a biomimetic nerve chip for evaluating the efficacy and toxicity of a drug, a method for evaluating the efficacy of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, and a method for evaluating the toxicity of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, the biomimetic nerve chip comprising: an astrocyte supply unit and a nerve cell supply unit for simulating nerve tissue; and a culture solution supply unit for supplying a culture solution to the astrocyte supply unit and the nerve cell supply unit. By using the biomimetic nerve chip for evaluating the efficacy and toxicity of a drug provided in the present invention, it is possible to overcome inaccuracies due to differences between the different species in animal experiments in the study of nerve tissues, and using a combination of astrocytes and nerve cells enables use of the nerve chip as a platform to more accurately evaluate the efficacy and toxicity of a drug under conditions similar to in vivo conditions, and the nerve chip can be applied to studies of microenvironments in nerve tissues and other organ-on-a-chip studies. Therefore, the present invention may be utilized in the development of a human-on-a-chip that can effectively analyze the efficacy and toxicity of a drug.

A system or method for detecting an immune system activation state in a patient can include a sample preparation system configured to isolate white blood cells from a sample of the patient, a cytometry module configured to determine biophysical properties of the white blood cells of the sample, and an analysis module configured to analyze the biophysical properties.

A modified melanoma cell line capable of quantification of the effects of MEK inhibitors and CDK4/6 inhibitors in a quantitative, temporal and non-invasive manner both in vitro and in vivo.

A method of predicting whether an MDS patient has a good or poor prognosis uses a general purpose computer configured as a classifier and mass-spectrometry data obtained from a blood-based sample. The classifier assigns a classification label of either Early or Late (or the equivalent) to the patient's sample. Patients classified as Early are predicted to have a poor prognosis or worse survival whereas those patients classified as Late are predicted to have a relatively better prognosis and longer survival time. The groupings demonstrated a large effect size between groups in Kaplan-Meier analysis of survival. Most importantly, while the classifications generated were correlated with other prognostic factors, such as IPSS score and genetic category, multivariate and subgroup analysis showed that they had significant independent prognostic power complementary to the existing prognostic factors.